TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01590771
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.
Study: NCT01590771
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.
Study: NCT01516203
Drug: Ethambutol, isoniazid, pyrazinamide, rifampin
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible subjects will be randomly assigned to receive treatment with standard 4 drug anti-tuberculosis regimen: Rifafour e-275 mg tablets (75 mg isoniazid/150 mg Rifampin/275 mg Ethambutol/400 mg Pyrazinamide) orally, dosed by body weight for 14 days.
Study: NCT00247702
Drug: warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005845
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02746757
Drug: Exendin 9-39
Normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00892190
Drug: dasatinib (SPRYCEL)
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours
Study: NCT00892190
Drug: all trans retinoic acid (VESANOID)
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 22.5mg/m2 every 12 hours
Study: NCT06217887
Drug: loxenatide Group
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loxenatide will be initiated and maintained at 0.2mg once weekly until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
Study: NCT06217887
Drug: Gliclazide Group
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
Study: NCT00033982
Drug: Posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01251822
Drug: Prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients less than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by two prucalopride 1 mg tablets for 28 days.~Patients more than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by one prucalopride 1 mg tablet and one placebo tablet for 28 days.
Study: NCT02794025
Drug: Esmolol
Normalized name: Esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava. The initial dose was 0.05 mg/kg/min and was adjusted based on heart rate (HR) (target HR: 70 bpm \< HR \< 100 bpm within 72 hours).~Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.
Study: NCT01728207
Drug: IMMU-114
Normalized name: IMMU-114
DrugBank: IMMU-114 (DB18458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.
Study: NCT04447118
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg, once daily (QD), will be administered with water within 30 minutes after completion of a meal, at approximately the same time each day on a continuous daily dosing schedule, with 21 days as a cycle.
Study: NCT04447118
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2, once every 3 weeks (Q3W), will be administered by intravenous infusion over 1 hour, with 21 days as a cycle.
Study: NCT02189577
Drug: CHF 5259
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
Study: NCT00155883
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02604797
Drug: Nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient-controlled intravenous analgesia
Study: NCT02604797
Drug: flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient-controlled intravenous analgesia
Study: NCT02604797
Drug: ramosetron
Normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: patient-controlled intravenous analgesia
Study: NCT02427958
Drug: Leuprorelin
Normalized name: Leuprorelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suspension for injection.
Study: NCT00204516
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given s.c. as adjuvant drug one day after vaccine
Study: NCT01802515
Drug: Atomoxetine, low dose
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.
Study: NCT01802515
Drug: Atomoxetine, high dose
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.
Study: NCT00127088
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04321278
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
Study: NCT02108652
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1200 mg given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria/loss of clinical benefit or unmanageable toxicity.
Study: NCT00001383
Drug: PSC 833
Normalized name: PSC-04
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001383
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00913783
Drug: Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)
Normalized name: clomipramine
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00913783
Drug: Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)
Normalized name: clomipramine Oral Capsule [Anafranil]
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01095913
Drug: Indocyanine green (ICG)
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
Study: NCT03311269
Drug: Sodium Tetradecyl Sulfate 1% Injection
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Tetradecyl Sulfate STS 1% Injection
Study: NCT03311269
Drug: Sodium Tetradecyl Sulfate 3% Injection
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Tetradecyl Sulfate 3% Injection
Study: NCT01481519
Drug: Artificial Tears
Normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: artificial tears 1 drop, 4 times per day
Study: NCT01182181
Drug: Anastrozole (Teva Pharmaceuticals USA)
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg Tablets
Study: NCT01182181
Drug: Anastrozole (Arimidex®)
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg Tablets
Study: NCT03756064
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib: 400mg orally daily
Study: NCT03756064
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;
Study: NCT03756064
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel: 75mg/m2 for a total of 6 cycles
Study: NCT03756064
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin: AUC=5 for a total of 6 cycles
Study: NCT00056329
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1,000 international units twice daily for three years
Study: NCT00056329
Drug: multivitamin
Normalized name: multivitamin
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily for three years
Study: NCT01086618
Drug: systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000232
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01539408
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of 400 mcg misoprostol administered sublingually
Study: NCT01980524
Drug: acipimox
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02413593
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT02571205
Drug: Sustanon (testosterone)
Normalized name: Testosterone
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard incremental regimen of Sustanon
Study: NCT00634985
Drug: eletriptan
Normalized name: Eletriptan
DrugBank: Eletriptan (DB00216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg oral tablet for migraine attack; additional 40 mg oral tablet \>2 hours from first dose if migraine reoccurred within 24 hours of achieving response
Study: NCT03845075
Drug: Tesofensine/Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During Part 1 subjects will be randomized to treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol (active medication)
Study: NCT01183715
Drug: PF-05161704 or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
Study: NCT00690378
Drug: NXL104/ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125mg/500mg TID
Study: NCT00690378
Drug: Imipenem/Cilastatin
Normalized name: imipenem/cilastatin/relebactam
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 x daily
Study: NCT01209741
Drug: telcagepant potassium
Normalized name: Potassium
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[INTERVENTION NAME: MK-0974 12MoRT\] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods
Study: NCT00904683
Drug: LY2062430
Normalized name: LY2062430
DrugBank: Solanezumab (DB11756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg intravenously (IV) every 4 weeks for 80 weeks
Study: NCT00992121
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I
Study: NCT00992121
Drug: Pazopanib 2 week
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons.
Study: NCT00992121
Drug: Pazopanib 3 week
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons.
Study: NCT00829660
Drug: Acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
Study: NCT02801409
Drug: Combined epidural-general anesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.
Study: NCT04593706
Drug: Betamethasone acetate + Betamethasone sodium phosphate
Normalized name: Betamethasone Acetate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
Study: NCT04593706
Drug: Dexamethasone sodium phosphate
Normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
Study: NCT04593706
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
Study: NCT04593706
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
Study: NCT02115919
Drug: Leukocyte Interleukin, Injection 200IU
DrugBank: Leukocyte interleukin (DB17315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort A participants will receive 200IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then 14 days off with out any Multikine injections received. After the 14 days without receiving the Investigational Product injections they will begin a second round of 200IU Multikine perilesional injections once daily, Monday through Friday for 14 days.
Study: NCT02115919
Drug: Leukocyte Interleukin, injection 400IU
DrugBank: Leukocyte interleukin (DB17315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort B participants will receive 400IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then they will not receive any Multikine perilesional injections for 14 days. After the 14 day rest period when the participants did not receive the Investigational Product injections they will begin a second round of 400IU Multikine perilesional injections every day, Monday through Friday, for 14 days.
Study: NCT02937896
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 micrograms Nasal Desmopressin.
Study: NCT01052389
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients allocated to aripiprazole will be prescribed daily oral dose of drug, based on individual response and side-effects. Suggested starting dose will be 10 mg/day and dose range will be 10-30 mg/day.
Study: NCT01052389
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients allocated to olanzapine will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden. Suggested starting dose will be 5 mg/day and dose range will be 10-20 mg/day.
Study: NCT01052389
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients allocated to haloperidol FGA arm will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden.~Suggested starting dose will be 1-3 mg/day and dose range 3-10 mg/day (chlorpromazine equivalents: suggested starting dose 50-100 mg/day; dose range 150-300 mg/day).
Study: NCT01721746
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01721746
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01721746
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04515628
Drug: Branebrutinib
Normalized name: Branebrutinib
DrugBank: Branebrutinib (DB15347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT00224978
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02411708
Drug: SANGUINATE
Normalized name: Sanguinate
DrugBank: Pegylated carboxyhemoglobin (bovine) (DB17720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single two-hour infusion of SANGUINATE
Study: NCT00537329
Drug: Anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eligible subjects will be initiated on a single loading dose of 200 mg IV anidulafungin, followed by 100 mg IV anidulafungin once daily for a minimum of 5 days but not more than 42 days.
Study: NCT00818103
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 40mg p.o. qn for 2 years
Study: NCT00818103
Drug: β-interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-interferon 50ug i.m. qod for 2 years
Study: NCT00818103
Drug: EPO
Normalized name: Epo B
DrugBank: Patupilone (DB03010)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO 10000U i.h. bid for 5 days
Study: NCT00612703
Drug: ARQ 197
Normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with ARQ 197 in combination with erlotinib
Study: NCT00871351
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
Study: NCT00871351
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
Study: NCT02425241
Drug: CPHPC
Normalized name: CPHPC
DrugBank: Miridesap (DB13087)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg CPHPC IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
Study: NCT02049515
Drug: IPI-145
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PI3K Inhibitor
Study: NCT02049515
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal antibody
Study: NCT01308268
Drug: Ivermectin + Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin: 200µg/kg, single dose, PO + Albendazole 200 (children between 12 and 23 months) or 400 mg (\>= 2 years old) single dose, PO
Study: NCT00871351
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
Study: NCT00208585
Drug: sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01184898
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus, by mouth, will be given as a 12mg loading dose followed by 8 daily doses of 4mg/day.
Study: NCT01184898
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone 8mg/m2/day IV
Study: NCT01184898
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m2/day IV
Study: NCT01184898
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2/day IV every 24 hours for 5 days
Study: NCT02906085
Drug: Endothelin-1
Normalized name: Endothelin-1
DrugBank: Endothelin-1 (DB12652)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03159078
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of Poly B monotherapy vs Polymyxin B plus carbapenem in MDR infections
Study: NCT00868764
Drug: granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days